Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer’s disease: study protocol for a randomised controlled trial (ELAD study)

Background Liraglutide is a glucagon-like peptide-1 (GLP-1) analogue currently approved for type 2 diabetes and obesity. Preclinical evidence in transgenic models of Alzheimer’s disease suggests that liraglutide exerts neuroprotective effects by reducing amyloid oligomers, normalising synaptic plast...

Full description

Saved in:

Bibliographic Details
Published in:	Current controlled trials in cardiovascular medicine Vol. 20; no. 1; pp. 191 - 10
Main Authors:	Femminella, Grazia Daniela, Frangou, Eleni, Love, Sharon B., Busza, Gail, Holmes, Clive, Ritchie, Craig, Lawrence, Robert, McFarlane, Brady, Tadros, George, Ridha, Basil H., Bannister, Carol, Walker, Zuzana, Archer, Hilary, Coulthard, Elizabeth, Underwood, Ben R., Prasanna, Aparna, Koranteng, Paul, Karim, Salman, Junaid, Kehinde, McGuinness, Bernadette, Nilforooshan, Ramin, Macharouthu, Ajay, Donaldson, Andrew, Thacker, Simon, Russell, Gregor, Malik, Naghma, Mate, Vandana, Knight, Lucy, Kshemendran, Sajeev, Harrison, John, Brooks, David J., Passmore, Anthony Peter, Ballard, Clive, Edison, Paul
Format:	Journal Article
Language:	English
Published:	London BioMed Central 03.04.2019 BioMed Central Ltd Springer Nature B.V BMC
Subjects:	Activities of Daily Living Alzheimer Disease - drug therapy Alzheimer Disease - metabolism Alzheimer Disease - physiopathology Alzheimer Disease - psychology Alzheimer's disease Antidiabetics Apoptosis Batteries Biomarkers Biomedicine Brain Brain - drug effects Brain - metabolism Brain - physiopathology Brain research Care and treatment Cell growth Cerebral glucose metabolic rate Clinical trials Clinical Trials, Phase II as Topic Cognition & reasoning Cognition - drug effects Dementia Development and progression Diabetes Double-Blind Method Drug dosages Genetic engineering Glucagon Glucagon-Like Peptide-1 Receptor - metabolism Glucagon-Like Peptide-1 Receptor Agonists Glucose Glucose - metabolism Growth factors Health Sciences Humans Hypoglycemic Agents - adverse effects Hypoglycemic Agents - therapeutic use Insulin Liraglutide Liraglutide - adverse effects Liraglutide - therapeutic use Medical research Medicine Medicine & Public Health Memory Memory - drug effects Metabolism Morbidity Multicenter Studies as Topic Neurons Neuroprotective Agents - adverse effects Neuroprotective Agents - therapeutic use Obesity Oligomers Peptides Phosphorylation Physiology Proteins Randomised controlled trial Randomized Controlled Trials as Topic Severity of Illness Index Statistics for Life Sciences Study Protocol Time Factors Tomography Treatment Outcome Type 2 diabetes United Kingdom United Kingdom Cerebral glucose metabolic rate Alzheimer’s disease Liraglutide Randomised controlled trial Dementia
ISSN:	1745-6215, 1745-6215
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!